BioGaia AB

BIOG B

SE0017769995

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 16/07/2024 pm IST			5-day change	1st Jan Change
127.1 ^SEK	+2.91%		+3.25%	+25.59%

05/06	BioGaia AB Establishes Its Own Distribution in Australia and New Zealand	CI
07/05	Nordic Shares Closed Up Tuesday; Storskogen Group Series B Topped Leaders	DJ

BioGaia Signs Exclusive Agreement with Abbott for the Rights to Commercialize Biogaia Products in the Area of Paediatrics and Gastroenterology in Thailand

January 13, 2017 at 12:30 pm IST

BioGaia has signed an exclusive agreement with Abbott for the rights to commercialize BioGaia products in the area of paediatrics and gastroenterology in Thailand. The products will be co-branded under BioGaia and Abbott brand. Launch of the products is planned to 2017.

Latest news about BioGaia AB

BioGaia AB Establishes Its Own Distribution in Australia and New Zealand	05/06	CI
Nordic Shares Closed Up Tuesday; Storskogen Group Series B Topped Leaders	07/05	DJ
Transcript : BioGaia AB, Q1 2024 Earnings Call, May 07, 2024	07/05
BioGaia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Nordic Shares Rose Wednesday; BW LPG Led Increases	03/04	DJ
Nordic Shares Decreased Thursday; BioGaia Series B Posted Biggest Loss	28/03	DJ
Nordic Stocks Moved Upward Wednesday; Nordic Semiconductor Climbed Highest	07/02	DJ
BioGaia AB to Seeks Acquisitions	07/02	CI
Transcript : BioGaia AB, Q4 2023 Earnings Call, Feb 07, 2024	07/02
BioGaia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/02	CI
BioGaia AB Proposes an Extra Dividend, Payable on May 15, 2024	07/02	CI
Biogaia AB Proposes Ordinary Dividend, Payable on May 15, 2024	07/02	CI
Transcript : BioGaia AB, Q3 2023 Earnings Call, Oct 20, 2023	20/23/20
BioGaia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	20/23/20	CI
BioGaia AB Announces Nomination Committee for the 2024 Annual General Meeting	18/23/18	CI
Biogaia AB Provides Preliminarily Earnings Guidance for Third Quarter 2023	17/23/17	CI
Biogaia AB Appoints Theresa Agnew as CEO	25/23/25	CI
BioGaia AB Introduces BioGaia Prodentis KIDS in Sweden	01/23/01	CI
BioGaia Names New CEO	02/23/02	MT
BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023	02/23/02	CI
Transcript : BioGaia AB, Q2 2023 Earnings Call, Jul 21, 2023	21/23/21
BioGaia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/23/21	CI
Nordic Shares Moved Upward Wednesday; Storskogen Group Series B Climbed Highest	12/23/12	DJ
BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults	05/23/05	CI
BioGaia AB Approves Election of Barbro Fridén, Outi Armstrong and Vesa Koskinen as Board Members	05/23/05	CI

Chart BioGaia AB

Duration

Period

More charts

Company Profile

Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Companyâs activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licenseeâs dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.

Sector

Pharmaceuticals

Calendar

23/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for BioGaia AB

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

127.1 SEK

Average target price

150 SEK

Spread / Average Target

+18.02%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BIOGAIA AB	+25.59%	117.86Cr
CSL LIMITED	+7.12%	10TCr
SAMSUNG BIOLOGICS CO.,LTD.	+8.42%	4.22TCr
BIOGEN INC.	-13.04%	3.23TCr
UCB	+80.80%	2.98TCr
BIOMARIN PHARMACEUTICAL INC.	-10.92%	1.61TCr
INCYTE CORPORATION	+1.93%	1.44TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.77%	1.2TCr
ALTEOGEN INC.	+177.16%	1.07TCr
SWEDISH ORPHAN BIOVITRUM AB	+4.12%	889.02Cr

Biopharmaceuticals

BioGaia AB

Equities

BIOG B

SE0017769995

Pharmaceuticals

BioGaia Signs Exclusive Agreement with Abbott for the Rights to Commercialize Biogaia Products in the Area of Paediatrics and Gastroenterology in Thailand

Latest news about BioGaia AB

Chart BioGaia AB

Company Profile

Income Statement Evolution

Ratings for BioGaia AB

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals